Mapping Chemotherapy-induced Peripheral Neuropathy Phenotype and Health-related Quality of Life in Patients with Cancer Through Exploratory Analysis of Multimodal Assessment Data

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2022 Jan 21

PMID 35059866

Authors

Mian Wang

Alex Molassiotis

Affiliations

Soon will be listed here.

Abstract

Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of anticancer treatment based on neurotoxic agents, which may affect function and health-related quality of life (HRQoL) in patients with cancer. This exploratory study aimed to identify the phenotype of CIPN and examine the association of CIPN with general symptoms and HRQoL in patients with cancer.

Methods: A secondary analysis was performed on the baseline multimodal assessment data of 87 patients with cancer who participated in a randomized trial examining the effectiveness of an 8-week acupuncture protocol in managing CIPN. The data used for this study include patient-reported CIPN, general symptoms, and HRQoL, neurological examinations, and clinician-based grading of CIPN. Descriptive statistics, non-parametric tests, and hierarchical cluster analysis were used for data analysis.

Results: Patients with CIPN experienced a series of symptoms, with numbness, tingling, and discomfort in the hands and feet being the most prominent descriptors pertaining to CIPN. Increased severity of CIPN was associated with higher distress from general symptoms and lower physical well-being. These CIPN-specific and general symptoms formed five independent symptom clusters, including two sensory neuropathy symptom clusters, a sensorimotor neuropathy one, a neuro-psychological one, and an autonomic symptom cluster. Painful CIPN was significantly associated with higher symptom burden, lower physical well-being, and impaired tendon reflex. No significant difference was found between type of neurotoxic agents in symptom burden, neurological signs, and HRQoL.

Conclusion: Researchers and clinicians should pay attention to the characteristics and impact of CIPN from multiple aspects, so as to develop targeted interventions to meet patients' holistic needs. Painful CIPN warrants particular attention as it is associated with higher symptom burden and lower physical well-being in patients with cancer.

Citing Articles

Preliminary evaluation of novel Bodily Attention Task to assess the role of the brain in chemotherapy-induced peripheral neurotoxicity (CIPN).

Manuweera T, Wagenknecht A, Kleckner A, Dorsey S, Zhu S, Tivarus M Behav Brain Res. 2023; 460:114803.

PMID: 38070689 PMC: 10860373. DOI: 10.1016/j.bbr.2023.114803.

Combination chemotherapy in rodents: a model for chemotherapy-induced neuropathic pain and pharmacological screening.

Akhilesh , Uniyal A, Mehta A, Tiwari V Metab Brain Dis. 2023; 39(1):43-65.

PMID: 37991674 DOI: 10.1007/s11011-023-01315-2.

Wellbeing and Complementary Therapies in Breast Cancer Peripheral Neuropathy Care: A Scoping Review Focused on Foot Health.

Veiga-Seijo R, Perez-Lopez M, Fernandez-Lopez U, Mosquera-Fernandez A, Seijo-Bestilleiro R, Gonzalez-Martin C Cancers (Basel). 2023; 15(7).

PMID: 37046771 PMC: 10093670. DOI: 10.3390/cancers15072110.

References

Brown T, Sedhom R, Gupta A . Chemotherapy-Induced Peripheral Neuropathy. JAMA Oncol. 2019; 5(5):750. DOI: 10.1001/jamaoncol.2018.6771. View

Kerckhove N, Collin A, Conde S, Chaleteix C, Pezet D, Balayssac D . Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Front Pharmacol. 2017; 8:86. PMC: 5323411. DOI: 10.3389/fphar.2017.00086. View

Shah A, Hoffman E, Mauermann M, Loprinzi C, Windebank A, Klein C . Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry. 2018; 89(6):636-641. PMC: 5970026. DOI: 10.1136/jnnp-2017-317215. View

Seretny M, Currie G, Sena E, Ramnarine S, Grant R, Macleod M . Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014; 155(12):2461-2470. DOI: 10.1016/j.pain.2014.09.020. View

Bennedsgaard K, Ventzel L, Themistocleous A, Bennett D, Jensen A, Jensen A . Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy. Cancer Med. 2020; 9(14):5114-5123. PMC: 7367625. DOI: 10.1002/cam4.3129. View

Kolb N, Smith A, Singleton J, Beck S, Stoddard G, Brown S . The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. JAMA Neurol. 2016; 73(7):860-6. PMC: 6715416. DOI: 10.1001/jamaneurol.2016.0383. View

Winters-Stone K, Horak F, Jacobs P, Trubowitz P, Dieckmann N, Stoyles S . Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol. 2017; 35(23):2604-2612. PMC: 5549452. DOI: 10.1200/JCO.2016.71.3552. View

Bonhof C, Mols F, Caroline Vos M, Pijnenborg J, Boll D, Vreugdenhil G . Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study. Gynecol Oncol. 2018; 149(3):455-463. DOI: 10.1016/j.ygyno.2018.03.052. View

Bonhof C, van de Poll-Franse L, Wasowicz D, Beerepoot L, Vreugdenhil G, Mols F . The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients. J Cancer Surviv. 2020; 15(2):190-200. PMC: 7966630. DOI: 10.1007/s11764-020-00923-6. View

10.

Loprinzi C, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz D . Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020; 38(28):3325-3348. DOI: 10.1200/JCO.20.01399. View

11.

Simon N, Danso M, Alberico T, Basch E, Bennett A . The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. Qual Life Res. 2017; 26(10):2763-2772. DOI: 10.1007/s11136-017-1635-0. View

12.

Wang M, Cheng H, Lopez V, Sundar R, Yorke J, Molassiotis A . Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time. BMC Cancer. 2019; 19(1):1151. PMC: 6882224. DOI: 10.1186/s12885-019-6352-3. View

13.

McCrary J, Goldstein D, Boyle F, Cox K, Grimison P, Kiernan M . Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support Care Cancer. 2017; 25(11):3485-3493. DOI: 10.1007/s00520-017-3772-y. View

14.

Haryani H, Fetzer S, Wu C, Hsu Y . Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review. Oncol Nurs Forum. 2017; 44(3):E111-E123. DOI: 10.1188/17.ONF.E111-E123. View

15.

Knoerl R, Chornoby Z, Smith E . Estimating the Frequency, Severity, and Clustering of SPADE Symptoms in Chronic Painful Chemotherapy-Induced Peripheral Neuropathy. Pain Manag Nurs. 2018; 19(4):354-365. DOI: 10.1016/j.pmn.2018.01.001. View

16.

Molassiotis A, Suen L, Cheng H, Mok T, Lee S, Wang C . A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy. Integr Cancer Ther. 2019; 18:1534735419836501. PMC: 6434440. DOI: 10.1177/1534735419836501. View

17.

Huang H, Brady M, Cella D, Fleming G . Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007; 17(2):387-93. DOI: 10.1111/j.1525-1438.2007.00794.x. View

18.

Forstenpointner J, Ruscheweyh R, Attal N, Baron R, Bouhassira D, Enax-Krumova E . No pain, still gain (of function): the relation between sensory profiles and the presence or absence of self-reported pain in a large multicenter cohort of patients with neuropathy. Pain. 2020; 162(3):718-727. DOI: 10.1097/j.pain.0000000000002058. View

19.

Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C . The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007; 12(3):210-5. DOI: 10.1111/j.1529-8027.2007.00141.x. View

20.

Lakshman A, Modi M, Prakash G, Malhotra P, Khadwal A, Jain S . Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction. Clin Lymphoma Myeloma Leuk. 2017; 17(8):513-519.e1. DOI: 10.1016/j.clml.2017.06.035. View